Search

Author/Creator Bittner, T.

1. P06 Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1–42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD. Issue 8 (August 2019)

Authors:
Grimmer, T.; Rabe, C.; Navarro, M.; Clayton, D.; Manuilova, E.; Peters, O.; Eichenlaub, U.; Smith, J.; Ostrowitzki, S.; Honigberg, L.; Bittner, T.
Journal:
Clinical neurophysiology
Issue:
Volume 130:Issue 8(2019:Aug.)
Page Start:
e148
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results. Issue 4 (April 2020)

Authors:
Bittner, T.; Duning, T.; Rabe, C.; Clayton, D.; Quartino, A.; Bohorquez, S. Sanabria; Hu, N.; Rabbia, M.; Shimizu, H.; Eichenlaub, U.; Smith, J.; Honigberg, L.; Selkoe, D.J.; Ostrowitzki, S.
Journal:
Clinical neurophysiology
Issue:
Volume 131:Issue 4(2020:Apr.)
Page Start:
e194
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. (31st March 2021)

Authors:
Liss, J. L.; Seleri Assunção, S.; Cummings, J.; Atri, A.; Geldmacher, D. S.; Candela, S. F.; Devanand, D. P.; Fillit, H. M.; Susman, J.; Mintzer, J.; Bittner, T.; Brunton, S. A.; Kerwin, D. R.; Jackson, W. C.; Small, G. W.; Grossberg, G. T.; Clevenger, C. K.; Cotter, V.; Stefanacci, R.; Wise‐Brow...
Journal:
Journal of internal medicine
Issue:
Volume 290:Number 2(2021)
Page Start:
310
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗